Browse the evidence

Dietary protein for athletic populations serves as a signal and substrate for muscle protein synthesis (MPS), aiding in hypertrophy, repair of damaged proteins, and maintenance of lean mass.

Athletes should focus on protein intake to enhance muscle growth and recovery.

Adults generally need no more than 0.8–0.9 g/kg/d of protein to meet their needs.

Adults should aim for a protein intake within this range to meet their nutritional needs.

Subjects in the weight loss program reduced their weight by 6.2% ±2.1%.

Practitioners can expect significant weight loss in participants following a structured diet and exercise program.

The combined compliance rate for the diet and exercise program averaged 92.9%.

A high combined compliance rate suggests that the program was well-received and effective.

A maintenance dose of 1.2 g·d-1 of beta-alanine (BA) was effective in maintaining performance during repeated sprints.

Practitioners can consider a lower maintenance dose of beta-alanine to sustain performance in repeated sprint activities.

Weight loss is the primary determinant of risk reduction in lifestyle programs to prevent diabetes.

Practitioners should prioritize weight loss strategies in diabetes prevention programs.

The quality of macronutrient content is more important than quantity for glycemic control.

Focus on the quality of foods rather than just calorie counting in dietary plans.

Low glycemic carbohydrates and replacement of saturated fats with unsaturated fats are beneficial for glycemic control and CVD risk reduction.

Encourage the consumption of low glycemic foods and healthy fats in dietary recommendations.

Strength training can improve endurance performance.

Incorporating strength training may benefit endurance athletes.

Muscular adaptations occur as a response to training.

Training programs should focus on inducing muscular adaptations for performance improvement.

The co-ingestion of caffeine with carbohydrate results in a 66% higher rate of muscle glycogen resynthesis during a 4-hour recovery period compared to carbohydrate alone.

Combining caffeine with carbohydrate can significantly enhance glycogen recovery post-exercise.

Caffeine co-ingestion leads to higher muscle glycogen accumulation after 4 hours of recovery compared to carbohydrate alone.

For optimal glycogen recovery, athletes may benefit from consuming caffeine with carbohydrates.

There were statistically significant reductions in all craving variables in the intervention group compared to the controls.

Weight loss interventions may effectively reduce food cravings.

Changes in craving-trait were significantly associated with weight change after controlling for baseline weight, age, gender and worksite.

Monitoring craving-trait changes may help in predicting weight loss outcomes.

Hunger was the only significant predictor of weight change in a multivariate model including craving-trait and eating behaviors.

Addressing hunger may be more effective than focusing solely on cravings in weight loss strategies.

Resistance exercise increases rates of muscle protein synthesis (MPS) for up to 48 hours into recovery.

Resistance training should be incorporated into fitness regimens to enhance muscle recovery and growth.

Rapidly digested whey protein rich in essential amino acids, especially leucine, is particularly stimulatory for MPS.

Incorporating whey protein, particularly post-exercise, may enhance muscle recovery and growth.

Among individuals with central adiposity, replacing SSB with either ASB or USB had a favorable effect on body weight.

Practitioners may consider recommending ASB or USB for weight management in individuals with central adiposity.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Semaglutide led to a mean relative weight loss of 13.3 ± 11.3% after 12 months in adults with type 1 diabetes.

Practitioners can consider semaglutide as an effective option for weight management in overweight/obese patients with type 1 diabetes.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.